Stockreport

Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

Amicus Therapeutics, Inc.  (FOLD) 
Last amicus therapeutics, inc. earnings: 11/11 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.amicusrx.com/investor-relations
PDF 2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year 2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand Expecting 2024 [Read more]